Paper
Finasteride: a clinical review.
Published 1995 · GJ Gormley
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Q1 SJR score
70
Citations
4
Influential Citations
Abstract
Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.
Highly CitedStudy Snapshot
Finasteride effectively reduces dihydrotestosterone levels in the prostate and scalp without affecting testosterone levels, potentially benefiting men with enlarged prostates and potentially arresting benign prostatic hyperplasia progression.
PopulationOlder adults (50-71 years)
Sample size24
MethodsObservational
OutcomesBody Mass Index projections
ResultsSocial networks mitigate obesity in older groups.
Sign up to use Study Snapshot
Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.
Full text analysis coming soon...
References
The Potential Application of Finasteride for Chemoprevention of Prostate Cancer
Finasteride shows potential as a minimally invasive chemopreventive agent for prostate cancer, suppressing DHT formation and reducing the risk of developing androgen-resistant tumors.
1995·17citations·G. Gormley et al.·Annals of the New York Academy of Sciences
Annals of the New York Academy of Sciences
Treatment with finasteride following radical prostatectomy for prostate cancer.
Finasteride treatment delays but does not prevent the rise in serum PSA levels after radical prostatectomy, and may reduce local and distant recurrences without affecting the initial response to hormonal therapy.
1995·116citations·G. Andriole et al.·Urology
Urology
Clinical and hormonal effects of the 5 alpha-reductase inhibitor finasteride in idiopathic hirsutism.
Finasteride is a well-tolerated and useful tool in treating idiopathic hirsutism in women, with more pronounced clinical efficacy when combined with oral contraceptives.
1994·76citations·P. Moghetti et al.·The Journal of clinical endocrinology and metabolism
The Journal of clinical endocrinology and metabolism
Effects of finasteride, a 5 alpha-reductase inhibitor, on circulating androgens and gonadotropin secretion in hirsute women.
Finasteride significantly decreased dihydrotestosterone and hair growth in hirsute women without negatively affecting gonadotropin secretion.
1994·70citations·F. Fruzzetti et al.·The Journal of clinical endocrinology and metabolism
The Journal of clinical endocrinology and metabolism
CLINICAL-EXPERIENCE OF THE DETECTION OF PROSTATE-CANCER IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA TREATED WITH FINASTERIDE
Finasteride treatment for benign prostatic hyperplasia does not increase the risk of prostate cancer, as shown by the detection of 12 cases in the controlled study and evenly distributed among treatment groups.
1994·22citations·E. Stoner et al.·The Journal of Urology
The Journal of Urology
Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia.
Finasteride 5 mg is a safe and effective treatment for symptomatic benign prostatic hyperplasia, with a low-risk profile and long-term efficacy.
1994·203citations·Elizabeth Stoner·Urology
Urology
Effect of finasteride on serum PSA concentration in men with benign prostatic hyperplasia. Results from the North American phase III clinical trial.
Finasteride reduces prostate size and decreases serum PSA concentration in men with benign prostatic hyperplasia, affecting the interpretation of serum PSA levels.
1993·82citations·Harry A. Guess et al.·The Urologic clinics of North America
The Urologic clinics of North America
The effect of finasteride in men with benign prostatic hyperplasia.
Finasteride treatment (5 mg per day) significantly reduces urinary symptoms, increases urinary flow, and decreases prostatic volume in men with benign prostatic hyperplasia, but may increase sexual dysfunction risks.
1992·1001citations·G. Gormley et al.·The Journal of urology
The Journal of urology
Citations
Comparison of Testosterone Level of Seminal Vesicle Fluid in Patients With Prostate Cancer Versus Other Malignancies
Testosterone in seminal vesicles may contribute to prostate cancer incidence, but has no relationship with pathological grading or other malignancies.
2023·0citations·E. Kashiwagi et al.·AntiCancer Research
AntiCancer Research
Topical Lipid Based Drug Delivery Systems for Skin Diseases: A Review
Liposomes and SLNs enhance topical therapy for skin diseases by improving drug permeation, safety, and effectiveness, while reducing systemic side effects.
2020·6citations·S. Sahu et al.·Current Drug Therapy
Current Drug Therapy
Seaweeds as Source of Bioactive Substances and Skin Care Therapy—Cosmeceuticals, Algotheraphy, and Thalassotherapy
Algae produce bioactive compounds that can be used in cosmetics, algotheraphy, and thalassotherapy, offering potential benefits for health and well-being.
2018·194citations·L. Pereira·Cosmetics
Cosmetics
Development and evaluation of finasteride loaded ethosomes for targeting to the pilosebaceous unit
Finasteride loaded ethosomes show good permeation across the stratum corneum to reach the pilosebaceous unit, potentially enhancing treatment for androgenetic alopecia.
2017·30citations·Vinny Wilson et al.·Artificial Cells, Nanomedicine, and Biotechnology
Artificial Cells, Nanomedicine, and Biotechnology
Solubilizing steroidal drugs by β-cyclodextrin derivatives.
-cyclodextrin derivatives can improve the bioavailability of hydrophobic steroids, such as testosterone, estradiol, and progesterone, by increasing their solubility in water.
2017·51citations·Dennis H Schwarz et al.·International journal of pharmaceutics
International journal of pharmaceutics